top of page

Fzata Awards 2024

  • "Finalist" at BIO International Start-up Stadium

  • A Maryland Company @ BIO 2024 representing MD Dept. of Commerce  

  • Recipient of $10MM new NIH grants and in-kind awards 2024

Bioengineered Probiotic Yeast Medicine (BioPYM): a first-in-class platform for oral live biotherapeutics. 
www.nature.com/biopharmdeal   5 July 2023

Intro Video 2 min.

Our MISSION

Expand safety, efficacy & access for therapeutic biologics leveraging BioPYM  oral administration  

 

Our oral biologics for gastrointestinal (GI) disorders will:

  1. Improve patient safety with no systemic toxicities

  2. Improve efficacy with biologics targeted directly to GI where disease occurs

  3.  Improve patient accessibility to biologics with at home, non-refrigerated, convenient oral capsules

  4.  Improve patient compliance with no needles and no  health-care administrated infusion

  5.  Improve chronic use outcomes given the high safety profile, no ADA, no systemic toxicity

The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) uses yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases.  

syringe under prohibition sign

 Fzata, Inc. 1450 S. Rolling Rd,  Room 4.097,  Halethorpe, Maryland 21227  USA

 443.543.5040          info (type @) fzata.com

bottom of page